ThromboGenics Announces Progress With Its Pre-clinical and Clinical Programs
Lead pre-clinical candidate TB- 403 (Anti-PlGF) set to enter the clinic in late 2007
04-May-2007 -
ThromboGenics NV provided an update highlighting progress with its pre-clinical development portfolio. As part of this update, the Company announced an out-licensing agreement for the antibodies against platelet glycoprotein Ib (anti-GPIb) and von Willebrand Factor (anti-vWF), which it has been ...
angiogenesis
antibodies
bone marrow
+8